novemb
reuter
health
maha
el
dahan
saudi
citizen
capit
riyadh
world
third
confirm
case
newli
discov
sever
acut
respiratori
syndrom
sar
viru
recov
ill
offici
saudi
press
agenc
report
potenti
deadli
novel
coronaviru
famili
sar
confirm
previou
case
saudi
man
die
earlier
year
man
qatar
treat
london
hospit
world
health
organ
put
global
alert
septemb
viru
later
ad
appear
spread
easili
person
person
coronavirus
also
includ
strain
caus
common
cold
well
sar
emerg
china
kill
around
tenth
peopl
infect
worldwid
saudi
arabia
taken
precaut
prevent
diseas
spread
among
muslim
pilgrim
annual
haj
pilgrimag
took
place
end
octob
million
muslim
countri
flock
mecca
medina
haj
season
perform
annual
religi
ritual
saudi
arabia
said
time
take
prevent
measur
stop
viru
spread
editori
comment
decemb
total
confirm
case
saudi
arabia
death
qatar
jordan
death
cluster
case
plu
unconfirm
case
saudi
famili
case
unconfirm
case
mainli
among
health
care
worker
hospit
jordan
genom
analysi
coronaviru
involv
earlier
case
indic
closest
rel
coronaviru
bat
viru
identifi
netherland
turn
close
relat
bat
coronavirus
detect
hong
kong
copyright
reuter
limit
mmwr
august
california
depart
public
health
announc
confirm
case
hantaviru
pulmonari
syndrom
hp
california
resid
stay
overnight
yosemit
nation
park
launch
investig
nation
park
servic
california
depart
public
health
center
diseas
control
prevent
august
yosemit
nation
park
announc
addit
case
octob
case
confirm
nation
park
servic
notifi
email
telephon
mail
regist
overnight
yosemit
nation
park
visitor
approxim
guest
stay
park
septemb
confirm
patient
came
state
california
west
virginia
pennsylvania
age
rang
year
year
femal
nine
patient
typic
symptom
hp
lack
respiratori
symptom
die
nine
patient
stay
curri
villag
signatur
cabin
insul
canva
exterior
interior
hard
wall
rodent
infest
detect
insul
signatur
cabin
close
indefinit
august
addit
educ
intervent
enhanc
staff
member
visitor
parkwid
multifacet
rodent
control
measur
includ
trap
throughout
curri
villag
implement
hp
nation
notifi
diseas
caus
unit
state
commonli
sin
nombr
viru
deer
mous
peromyscu
maniculatu
reservoir
infect
mice
shed
viru
urin
fece
saliva
human
becom
infect
inhal
aerosol
viru
rodent
excreta
via
direct
contact
rodent
bite
incub
period
rang
week
earli
symptom
includ
fever
chill
myalgia
headach
gastrointestin
symptom
day
progress
rapidli
respiratori
distress
shock
patient
requir
hospit
supplement
oxygen
intub
casefat
rate
approxim
specif
treatment
hp
earli
support
care
reduc
mortal
outbreak
case
hp
report
among
california
resid
sinc
visitor
yosemit
nation
park
clinician
remind
consid
diagnosi
hantaviru
infect
person
febril
ill
sudden
onset
respiratori
symptom
histori
rodent
exposur
hp
report
diseas
unit
state
clinician
suspect
hp
notifi
consult
state
health
depart
confirmatori
test
park
visitor
public
advis
avoid
contact
rodent
urin
drop
nest
materi
novarti
news
releas
util
fullscal
cellcultur
manufactur
technolog
altern
product
method
tradit
eggbas
product
cellcultur
technolog
util
wellcharacter
mammalian
cell
line
rather
chicken
egg
grow
viru
strain
product
occur
close
steril
control
environ
significantli
reduc
risk
potenti
impur
flucelvax
contain
preserv
thimeros
antibiot
cellcultur
technolog
enabl
rapid
respons
urgent
public
health
need
pandem
within
week
tradit
influenza
vaccin
product
depend
larg
number
fertil
chicken
egg
grow
viru
strain
requir
mani
month
organ
egg
suppli
viru
incub
actual
product
vaccin
deliv
physician
pharmaci
cellcultur
technolog
success
use
manufactur
vaccin
includ
distribut
pandem
well
vaccin
polio
rubella
hepat
modern
cellcultur
technolog
like
becom
new
standard
influenza
vaccin
product
proud
lead
way
said
andrin
oswald
divis
head
novarti
vaccin
diagnost
avail
cellcultur
vaccin
import
step
ensur
readi
season
influenza
well
potenti
pandem
said
dr
william
schaffner
professor
medicin
chair
prevent
medicin
vanderbilt
univers
nashvil
tennesse
annual
influenza
vaccin
import
public
health
measur
help
protect
thousand
peopl
ill
death
year
editori
comment
develop
facil
capabl
use
cell
cultur
technolog
produc
influenza
vaccin
import
elimin
need
huge
number
egg
abil
respond
faster
vaccin
product
pandem
novemb
reuter
health
zeba
siddiqui
us
food
drug
administr
fda
panel
vote
unanim
recommend
effect
dynavax
inc
hepat
b
vaccin
heplisav
rais
concern
safeti
ask
data
studi
wider
popul
view
panel
outsid
expert
base
data
submit
dynavax
compar
safeti
immunogen
heplisav
engerix
b
older
vaccin
glaxosmithklin
plc
immunogen
data
provid
dynavax
excel
concern
popul
think
realli
realli
good
repres
unit
state
panel
member
said
dynavax
conduct
studi
patient
support
heplisav
market
approv
applic
patient
mainli
unit
state
canada
germani
year
older
prior
vote
panel
member
pepper
dynavax
question
advers
event
lack
suffici
represent
crosssect
popul
studi
pool
specif
asianamerican
africanamerican
hispan
fda
spokeswoman
rita
chappel
said
email
panel
member
assert
dynavax
focu
larger
databas
ethnic
divers
patient
higherrisk
popul
would
highlight
benefit
vaccin
promin
panel
member
favor
efficaci
profil
heplisav
eight
panel
member
question
safeti
vaccin
base
avail
data
favor
nt
think
safeti
databas
suffici
larg
support
recommend
use
vaccin
gener
adult
popul
given
contain
adjuv
anoth
member
said
product
need
safe
effect
intend
use
case
committe
felt
heplisav
meet
threshold
fda
chappel
said
brief
document
fda
staff
note
incid
autoimmun
event
heplisavengerix
b
studi
low
autoimmun
advers
event
occur
heplisav
arm
studi
fda
take
panel
opinion
consider
decid
whether
grant
market
approv
vaccin
editori
comment
heplisav
conjug
vaccin
given
month
apart
provid
reliabl
rapid
antibodi
respons
avail
hepat
b
vaccin
avail
vaccin
adult
requir
dose
given
month
provid
seroprotect
approxim
first
second
third
dose
respect
furthermor
mani
finish
cours
inject
copyright
reuter
limit
right
reserv
